Ablynx Announces Worldwide Cancer Immunotherapy Discovery Collaboration and Licensing Agreement with Merck Ablynx announced that the company has entered into a second research collaboration and licensing agreement with a subsidiary of Merck & Co. This new exclusive collaboration and licensing agreement is focused on the discovery and development of several predefined Nanobody candidates directed toward so called “immune checkpoint modulators,” proteins believed to provide potential targets for the development of cancer immunotherapies, a rapidly emerging approach to the treatment of a wide range of cancer types. [Ablynx] Press Release BrainStorm Signs Definitive Agreement with Mayo Clinic for ALS Clinical Trial and NurOwn Manufacturing BrainStorm Cell Therapeutics announced that it has signed a definitive agreement with the Mayo Clinic in Rochester, Minnesota to conduct its Phase II clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS), pending FDA approval. [BrainStorm Cell Therapeutics, Inc.] Press Release Oxford University and Syncona Announce the Formation of Nightstar, a Company Developing Retinal Gene Therapies Syncona LLP announced a £12 million investment in NightstaRx Ltd a spin-out from the University of Oxford and its research commercialization company Isis Innovation. Nightstar will focus on the development and commercialization of therapies for retinal dystrophies (degenerative conditions affecting vision). [Syncona LLP] Press Release Kiadis Pharma Initiates Collaboration for Personalized Immunotherapies Using ATIR™ with Technische Universität München within Munich Biotech Cluster Kiadis Pharma B.V. announced that it has initiated a collaboration to identify and characterize leukemia-specific T-cells in Kiadis Pharma’s lead product ATIR™, that would be responsible for the Graft-versus-Leukemia effect of the T-cell immunotherapy product. [Kiadis Pharma B.V.] Press Release STEMSOFT Software Inc. and JAF Consulting, Inc. Announce Collaborative Partnership STEMSOFT Software Inc. and JAF Consulting, Inc. announced their collaborative partnership. As a STEMSOFT Certified Consulting Partner, JAF will provide STEMSOFT clients the opportunity to engage in JAF’s expertise and individualized computer validation, regulatory compliance and quality systems management services. [STEMSOFT Software Inc.] Press Release Medigene Acquires Trianta Immunotherapies Medigene AG has acquired Trianta Immunotherapies GmbH, a spin-off of the Helmholtz Zentrum München. Trianta is developing three immunotherapy platforms with programs in clinical development to treat various tumor types. [Medigene AG] Press Release Stem Cell Agency Funds More than $66 Million in Research Including New Genomics Initiative A team bringing together experts and investigators from seven different major California institutions has been awarded $40 million to create a new Center of Excellence in Stem Cell Genomics, by California’s stem cell agency, the California Institute for Regenerative Medicine. [California Institute for Regenerative Medicine] Press Release Quest PharmaTech Announces Third Combinatorial Immunotherapy Clinical Trial for Oregovomab with a TLR3 Agonist, Hiltonol® Quest PharmaTech Inc. announced that it has entered into a license agreement with U.S. based Oncovir, Inc. (Washington, DC) to evaluate the clinical utility of combining Quest’s antibody immunotherapy technology with Oncovir’s immune activator “Hiltonol®” in a twenty patient ovarian cancer Phase II clinical trial. [Quest PharmaTech Inc.] Press Release Positive Spinal Disc Repair Trial Results Using Mesoblast Adult Stem Cells Mesoblast Limited announced positive 12 month outcome results from the 100-patient Phase II clinical trial of its proprietary allogeneic, or “off-the-shelf”, mesenchymal precursor cells in patients with chronic moderate to severe discogenic low back pain. [Mesoblast Limited] Press Release Experienced Stem Cell Product Developer to Join Cynata Cynata Therapeutics Ltd announced the appointment of Dr. Kilian Kelly as Vice President, Product Development. Dr. Kelly will be a member of Cynata’s executive management team and will lead the regulatory, pre-clinical and clinical development of the Company’s proprietary Cymerus™ mesenchymal stem cell product pipeline. [Cynata Therapeutics Ltd] Press Release |